70 related articles for article (PubMed ID: 19950813)
1. Practical value of applying cdc2 kinase shRNA to chronic proliferative cholangitis in treatment of hepatolithiasis.
Li FY; Cheng NS; Cheng JQ; Mao H; Jiang LS; Li QS; Zhou Y
Hepatogastroenterology; 2009; 56(94-95):1477-82. PubMed ID: 19950813
[TBL] [Abstract][Full Text] [Related]
2. Proliferating cell nuclear antigen shRNA treatment attenuates chronic proliferative cholangitis in rats.
Li FY; Cheng NS; Cheng JQ; Mao H; Zhou Y; Jiang LS; Li N
J Gastroenterol Hepatol; 2009 May; 24(5):920-6. PubMed ID: 19032457
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic proliferative cholangitis with c-myc shRNA.
Li FY; Cheng NS; Cheng JQ; Mao H; Jiang LS; Li N; He S
World J Gastroenterol; 2009 Jan; 15(1):95-101. PubMed ID: 19115473
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor as a target for anti-proliferative treatment of proliferative cholangitis in hepatolithiasis.
Li F; Zhou Y; Cheng N; Mao H; Jiang L; Li N; Li Q; de Jong MC; Pawlik TM
J Surg Res; 2011 Mar; 166(1):87-94. PubMed ID: 20097367
[TBL] [Abstract][Full Text] [Related]
5. Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.
Li FY; Cheng NS; Mao H; Jiang LS; Cheng JQ; Li QS; Munireddy S
World J Surg; 2009 Oct; 33(10):2155-60. PubMed ID: 19641953
[TBL] [Abstract][Full Text] [Related]
6. Effects of epidermal growth factor receptor inhibitor on proliferative cholangitis in hepatolithiasis.
Yang Q; Zhou Y; Li FY; Mao H; Shrestha A; Ma WJ; Cheng NS; Zhang W
Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):509-15. PubMed ID: 26459727
[TBL] [Abstract][Full Text] [Related]
7. Biliary antibiotics irrigation for E. coli-induced chronic proliferative cholangitis and hepatolithiasis: A pathophysiological study in rabbits.
Ma WJ; Wu ZR; Yang Q; Hu HJ; Wang JK; Shi YJ; Li FY; Cheng NS
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):356-367. PubMed ID: 31420296
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and therapeutic procedure with a short double-balloon enteroscope and cholangioscopy in a patient with acute cholangitis due to hepatolithiasis.
Takaoka M; Shimatani M; Ikeura T; Koyabu M; Kusuda T; Fukata N; Matsushita M; Okazaki K
Gastrointest Endosc; 2009 Dec; 70(6):1277-9. PubMed ID: 19559432
[No Abstract] [Full Text] [Related]
9. Down stream involvement of the bile duct in hepatolithiasis.
Lu S; Yan L; Rao L; Xia T; Gou J; Zhang S; Lei S
Chin Med J (Engl); 2002 Jan; 115(1):62-4. PubMed ID: 11930661
[TBL] [Abstract][Full Text] [Related]
10. Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide.
Yoshida M; Yamamoto N; Nitta T; Uehara T; Terao R; Hatano E; Iimuro Y; Yamaoka Y
J Surg Res; 2002 Feb; 102(2):95-101. PubMed ID: 11796004
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study of chemical bile duct embolization to treat hepatolithiasis in rabbits.
Li FY; Cheng JQ; Mao H; Li N; Jiang LS; He S; Cheng NS; Dong JH
J Gastroenterol Hepatol; 2006 Jun; 21(6):994-8. PubMed ID: 16724984
[TBL] [Abstract][Full Text] [Related]
12. The distribution of secretory immunoglobulin A in the liver of patients with hepatolithiasis.
Hamba H; Hirohashi K; Kubo S; Fujio N; Tanaka H; Kinoshita H
Osaka City Med J; 2002 Jun; 48(1):85-94. PubMed ID: 12375701
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of long-term results and recurrent factors after operative and nonoperative treatment for hepatolithiasis.
Cheon YK; Cho YD; Moon JH; Lee JS; Shim CS
Surgery; 2009 Nov; 146(5):843-53. PubMed ID: 19744434
[TBL] [Abstract][Full Text] [Related]
14. Clinical prospect of applying the chemical bile duct embolization to achieve a chemical hepatectomy in the treatment of highly selected hepatolithiasis.
Li FY; Jiang LS; de Jong MC; Cheng NS; Cheng JQ; Li N; Wu XW
Surg Laparosc Endosc Percutan Tech; 2009 Jun; 19(3):183-7; discussion 187-9. PubMed ID: 19542840
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of choledochoduodenostomy for hepatolithiasis.
Ling XF; Xu Z; Wang LX; Hou CS; Xiu DR; Zhang TL; Zhou XS
Chin Med J (Engl); 2010 Jan; 123(2):137-41. PubMed ID: 20137359
[TBL] [Abstract][Full Text] [Related]
16. Effects of epidermal growth factor receptor inhibitor genistein on proliferative cholangitis in rats.
Jiang L; Jiang LS; Yan LN; Li FY; Wang W; Cheng NS; Wen TF
J Surg Res; 2010 Jul; 162(1):59-67. PubMed ID: 19665144
[TBL] [Abstract][Full Text] [Related]
17. Effective Treatment of Chronic Proliferative Cholangitis by Local Gentamicin Infusion in Rabbits.
Yang Q; Wu Z; Liu F; Wang J; Ma W; Hu H; Li F; Pan Q
Biomed Res Int; 2018; 2018():6751952. PubMed ID: 30140699
[TBL] [Abstract][Full Text] [Related]
18. [Alterations of the mucin components in bile duct epithelium associated with proliferating cholangitis--an experimental study].
Katayama F
Hokkaido Igaku Zasshi; 1996 Sep; 71(5):585-98. PubMed ID: 8934203
[TBL] [Abstract][Full Text] [Related]
19. EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR.
Liu SH; Chen XF; Xie ZB; Zhou J
Int J Mol Med; 2019 Jul; 44(1):79-88. PubMed ID: 31115490
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of hepatic resection for hepatolithiasis.
Uenishi T; Hamba H; Takemura S; Oba K; Ogawa M; Yamamoto T; Tanaka S; Kubo S
Am J Surg; 2009 Aug; 198(2):199-202. PubMed ID: 19249730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
